CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals with a high unmet medical need. Although CAR-T cells have demonstrated promising efficacy in patients, there are several challenges that need to be overcome before these are optimally used in clinical practice.
In this podcast, you will hear from Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, and Natacha Bolaños, Lymphoma Coalition Europe, Madrid, Spain, who discuss two major barriers to CAR-T therapy: the high cost of CAR-T cells and the need to improve access to these agents.
The MDS Sessions: Giants in MDS
Latest therapies in AML: IMGN632, magrolimab & gilteritinib
VJSession: EBMT/EHA CAR-T Nursing Session
The Myeloma Sessions: key updates from ASH 2020
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
Updates for the management of MDS from ASH 2020
The AML Sessions: highlights from ASH 2020
The MDS Sessions: treating MDS around the world
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
Advances in CAR T-cell therapies for lymphoma from ASH 2020
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
The MDS sessions: lower-risk disease
The AML Sessions: FLT3-mutated disease
The Lymphoma Sessions: highlights from iwNHL 2020
The MDS sessions: clinical trial participation, endpoints & approvals
The AML sessions: venetoclax-based regimens
The AML Sessions: IDH inhibitors
The AML sessions: advances in immuno-oncology from SOHO 2020
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive